Biden Administration Slashes Medicare Drug Prices by Up to 79%

The Biden administration announced a pronounced reduction in the prices of 10 high-demand prescription drugs covered by Medicare, with discounts reaching up to 79%. This move, anticipated to save $6 billion in the first year, is part of the Inflation Reduction Act to address high drug prices ahead of upcoming elections.

The Biden administration announced on Thursday that it has successfully negotiated a reduction in the prices of 10 high-demand prescription drugs covered by Medicare, with reductions of up to 79%. The administration aims to save $6 billion in the first year, addressing public dissatisfaction over soaring drug prices ahead of the next elections.

President Joe Biden's Inflation Reduction Act, which became law in 2022, empowers Medicare to negotiate prices for some of the most expensive drugs it covers for 66 million people. The new prices, set to be implemented in 2026, reflect significant cuts but do not account for existing rebates and discounts. The estimated government savings from these negotiations, however, do consider these factors.

Among the most affected drugs, Merck & Co's diabetes medication Januvia will see a price reduction of 79%, while Novo Nordisk's insulin products will see a 76% cut. Although drug manufacturers objected, claiming it wouldn't lower out-of-pocket costs or could hinder innovation, Medicare beneficiaries will save $1.5 billion annually in out-of-pocket expenses starting in 2026. These savings will likely influence voter sentiments in the upcoming tightly contested election.